(Total Views: 666)
Posted On: 09/07/2020 5:21:31 PM
Post# of 154002
The last data for this group in the CD12 trial will be measured in 2 weeks. Then interim results will be viewed and interpreted.
Although the trial data is currently blinded for this group of patients for approximately another few weeks as additional data is gathered, I can't help but think of how Bruce Patterson believes that Leronlimab is likely to show good results in these patients who are more ill. It looks to me like tomorrow, although no one will know data until un-blinding in approximately a few weeks, is one point at which a significant amount of data will have been collected.
3 of the 5 endpoints are based on data from day 14 which is perhaps September 8, and
2 of the 5 endpoints including the primary endpoint are based on data from day 28
https://www.clinicaltrials.gov/ct2/show/NCT04...amp;rank=5
Although the trial data is currently blinded for this group of patients for approximately another few weeks as additional data is gathered, I can't help but think of how Bruce Patterson believes that Leronlimab is likely to show good results in these patients who are more ill. It looks to me like tomorrow, although no one will know data until un-blinding in approximately a few weeks, is one point at which a significant amount of data will have been collected.
3 of the 5 endpoints are based on data from day 14 which is perhaps September 8, and
2 of the 5 endpoints including the primary endpoint are based on data from day 28
https://www.clinicaltrials.gov/ct2/show/NCT04...amp;rank=5
(3)
(0)
There are no guarantees in investing. No one should consider these pages or posts to be financial advice. Everyone has a responsibility to verify and thoroughly learn more than what is referenced or written here, and everyone must take responsibility for their own investing decisions.
